Trevi Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Trevi Therapeutics Inc TRVI.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of ten analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -7 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Trevi Therapeutics Inc's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of $12.3 million.

• Trevi Therapeutics Inc shares had risen by 32.9% this quarter and gained 76.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Trevi Therapeutics Inc is $22.00, about 66.8% above its last closing price of $7.30

This summary was machine generated from LSEG data August 8 at 04:08 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)